Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
12 août 2024 08h00 HE
|
Caribou Biosciences, Inc.
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE...
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
06 août 2024 16h05 HE
|
Caribou Biosciences, Inc.
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL...
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
09 juil. 2024 08h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
02 juin 2024 19h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
30 mai 2024 16h01 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
07 mai 2024 16h05 HE
|
Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 mai 2024 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 10h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15 avr. 2024 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
04 avr. 2024 16h00 HE
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...